1 Big Catalyst for Amarin Investors... Maybe


Amarin investors, it's almost that time again. The FDA's Orange Book should be updated later this week and it may contain news regarding Vascepa. Whether the NCE decision is finally put to rest or if yet another delay is in the cards is anyone's guess. However, there are plenty of other aspects to Amarin's business that investors all need to pay attention to. In this video, health-care analyst Max Macaluso runs through the main issues investors need to watch in the coming weeks.

Can Amarin beat the odds?

Small biotech companies usually crash and burn when it comes to launching drugs, but can Amarin prove the doubters wrong with its new lipid-lowering drug? In our new premium research report, The Motley Fool's top biotech analyst offers an in-depth look at this drugmaker's upcoming opportunities, along with reasons to buy and sell this stock today. To find out more -- and receive a full year of free bonus updates as news develops -- simply click here now to claim your copy.

The article 1 Big Catalyst for Amarin Investors... Maybe originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.